US Oncology amends loan, modifying covenants and pricing

By Sara Rosenberg

New York, Dec. 4 - US Oncology Inc. amended its senior secured credit facility, revising financial covenants and pricing, according to an 8-K filed with the Securities and Exchange Commission Tuesday.

Under the amendment, pricing on the revolver can now range from Libor plus 200 basis points to 275 bps, based on leverage.

Pricing on the term loan B and the term loan C will be Libor plus 275 bps if leverage is greater than or equal to 4.50 to 1.00, and Libor plus 250 bps if leverage is less than 4.50 to 1.00.

The amendment was effective as of Nov. 30.

JPMorgan is the administrative agent on the deal.

US Oncology is a is a Houston-based cancer services company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.